Clinical Trials Logo

Hepatic Insufficiency clinical trials

View clinical trials related to Hepatic Insufficiency.

Filter by:

NCT ID: NCT01079091 Terminated - Clinical trials for Acute on Chronic Hepatic Failure

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

HEPATICUS-1
Start date: September 2010
Phase: N/A
Study type: Interventional

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

NCT ID: NCT00915681 Terminated - Liver Failure Clinical Trials

Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning

Start date: November 10, 2009
Phase: Phase 2
Study type: Interventional

Legalon® SIL will be administered to patients with amatoxin poisoning diagnosed by history, gastrointestinal symptoms, elevated liver enzymes, and/or diagnostic assay (should one become available). Patients may or may not also demonstrate abnormalities in bilirubin and/or creatinine. Treatment consists of a 5 mg/kg loading dose followed by 20 mg/kg/day via continuous infusion. The treating physician is expected to administer supportive therapy of his/her choosing but consistent with best practices. Legalon® SIL will be stopped when coagulopathy is no longer present, and when liver function tests have returned significantly towards the normal range. Patients will be followed 7-14 days after the end of Legalon® SIL therapy with follow up lab studies.

NCT ID: NCT00896025 Terminated - Acute Liver Failure Clinical Trials

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

ONAC
Start date: December 2008
Phase: Phase 4
Study type: Interventional

This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.